Huntington’s
Roche’s Huntington’s disease treatment disappoints in Phase III trial
March 23, 2021Manufacturing and Production Huntington's, Phase III trial, Roche, huntington's disease, tominersen
Roche has discontinued dosing in a Phase III trial of its tominersen treatment for Huntington’s disease, following discouraging initial data.
Teva and Intel team up to tackle Huntington’s with wearable tech
September 16, 2016Medical Communications Huntington's, Intel, Teva, wearable tech
Israeli pharma firm Teva is joining forces with technology giant Intel to tackle the debilitating disease Huntington’s with cutting-edge wearable …
Roche signs Huntington’s deal
April 10, 2013Research and Development, Sales and Marketing Huntington's, Isis, Roche
Roche is to pay California-based Isis Pharmaceuticals $30 million upfront to cement a new alliance in which the firms will …
Pharma pools trial data for brain disorder research
June 14, 2010Research and Development Alzheimer's, Huntington's, Parkinson's, clinical trials, partnerships
Leading pharma companies have come together for a major new research collaboration aimed at improving clinical trials for Alzheimer’s, Parkinson’s, …
Latest content
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
